Through the integration of large-scale whole exome sequencing project, Syntekabio has proven its ability to solve these imminent data mining and analytics problems for professionals in clinical institutions and life science R&D organizations.
Sunnyvale, CA (PRWEB) November 21, 2012
Meeting the increasing demand for next generation sequencing (NGS) based whole genome and exome data analysis, Syntekabio is proud to announce the successful completion of a pilot project in the test market of Korea. The company delivered an integrated system, Indexed multi-Genome Analysis (IGA), for the whole exome (1,000) and target (9,000) analysis to the National Project for Personalized Genomic Medicine Consortium (PGM21), which is composed of the leading biomedical institutions and hospitals in Korea.
Whole genome and exome data is being generated at a stunning rate, as the price point per base pair sequencing drops fast, far exceeding Moore’s Law, and the industry expects a $1,000/genome era by the end of this year. But the challenge of data mining and analytics is still the most significant bottleneck to the advancement of clinical application of genomic data.
Through the integration of large-scale whole exome sequencing project, Syntekabio has proven its ability to solve these imminent data mining and analytics problems for professionals in clinical institutions and life science R&D organizations, helping to realize a future of personalized medicine enabled by NGS-generated data.
Since its foundation in 2009, Syntekabio has built a ground-breaking biomedical data infrastructure utilizing proprietary search engine, data mining, and data analytics tools. The company leverages its analytics application for genotyping for risk-stratifying patients in order to comprehensively analyze the whole exome sequencing data, and has successfully developed and commercialized a core technology, conducting genome and exome comparative analysis on clinical genomes.
Additionally, Syntekabio developed a revolutionary method for comparing variants in a normal genome and a disease genome: the “reverse classification based genome comparison” technology (patent pending at PCT). This method promotes computation performance and increases accuracy by 10,000 times over the current method. Instead of starting by calling variants by genome sequencing raw data, the underlying algorithm enables users to first identify and confirm the differential raw data extracted from a normal genome and a disease genome, and later define mutations.
For more information on the NGS data analytics, please contact Syntekabio at cs(at)syntekabio(dot)com.
Founded in 2009, Syntekabio develops biomedical data mining and analytics solutions that help end users and decision-makers in clinical R&D to access, analyze, and visualize omics data. They are the first developer to integrate public biomedical databases of more than 750 million records and provide top-down biology workflows in a single search engine. Syntekabio is committed to making personalized medicine a reality by leveraging genomics and creating disease risk assessment tools.